132 related articles for article (PubMed ID: 10929426)
1. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
[TBL] [Abstract][Full Text] [Related]
2. Expression of the tumor-rejection antigen SART1 in brain tumors.
Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
[TBL] [Abstract][Full Text] [Related]
3. Expression of the SART3 tumor rejection antigen in renal cell carcinoma.
Kawagoe N; Shintaku I; Yutani S; Etoh H; Matuoka K; Noda S; Itoh K
J Urol; 2000 Dec; 164(6):2090-5. PubMed ID: 11061933
[TBL] [Abstract][Full Text] [Related]
4. Expression of the SART1 tumor-rejection antigen in hepatocellular carcinomas.
Yutani S; Shichijo S; Inoue Y; Kawagoe N; Okuda K; Kurohiji T; Tanaka M; Sata M; Itoh K
Oncol Rep; 2001; 8(2):369-72. PubMed ID: 11182058
[TBL] [Abstract][Full Text] [Related]
5. Expression of tumor-rejection antigens in gynecologic cancers.
Tanaka S; Tsuda N; Kawano K; Sakamoto M; Nishida T; Hashimoto T; Shichijo S; Kamura T; Itoh K
Jpn J Cancer Res; 2000 Nov; 91(11):1177-84. PubMed ID: 11092984
[TBL] [Abstract][Full Text] [Related]
6. Expression of the SART1 tumor-rejection antigen in human osteosarcomas.
Ishida H; Komiya S; Inoue Y; Yutani S; Inoue A; Itoh K
Int J Oncol; 2000 Jul; 17(1):29-32. PubMed ID: 10853014
[TBL] [Abstract][Full Text] [Related]
7. Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes.
Inoue Y; Nakao M; Matsunaga K; Kikuchi M; Gomi S; Toh U; Takamori S; Yamana H; Itoh K
J Immunother; 2000; 23(3):296-303. PubMed ID: 10838658
[TBL] [Abstract][Full Text] [Related]
8. Expression of the SART1 tumor-rejection antigens in colorectal cancers.
Sasatomi T; Yamana H; Shichijo S; Tanaka S; Okamura T; Ogata Y; Itoh K; Shirouzu K
Dis Colon Rectum; 2000 Dec; 43(12):1754-8. PubMed ID: 11156463
[TBL] [Abstract][Full Text] [Related]
9. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes.
Yamada A; Kawano K; Koga M; Matsumoto T; Itoh K
Cancer Res; 2001 Sep; 61(17):6459-66. PubMed ID: 11522641
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
13. Identification of an immunogenic CTL epitope of HIFPH3 for immunotherapy of renal cell carcinoma.
Sato E; Torigoe T; Hirohashi Y; Kitamura H; Tanaka T; Honma I; Asanuma H; Harada K; Takasu H; Masumori N; Ito N; Hasegawa T; Tsukamoto T; Sato N
Clin Cancer Res; 2008 Nov; 14(21):6916-23. PubMed ID: 18980986
[TBL] [Abstract][Full Text] [Related]
14. Expression of the SART-1 antigens in uterine cancers.
Matsumoto H; Shichijo S; Kawano K; Nishida T; Sakamoto M; Itoh K
Jpn J Cancer Res; 1998 Dec; 89(12):1292-5. PubMed ID: 10081490
[TBL] [Abstract][Full Text] [Related]
15. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL.
Nakao M; Shichijo S; Imaizumi T; Inoue Y; Matsunaga K; Yamada A; Kikuchi M; Tsuda N; Ohta K; Takamori S; Yamana H; Fujita H; Itoh K
J Immunol; 2000 Mar; 164(5):2565-74. PubMed ID: 10679095
[TBL] [Abstract][Full Text] [Related]
16. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
[TBL] [Abstract][Full Text] [Related]
17. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
[TBL] [Abstract][Full Text] [Related]
18. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
19. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
[TBL] [Abstract][Full Text] [Related]
20. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
